Navigation Links
BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
Date:11/29/2011

NOVATO, Calif., Nov. 29, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA (MPS IVA). 

"We expect this study to build our knowledge base in enzyme replacement therapies wherein clinicians believe earlier therapy is more impactful," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "Comparatively speaking, this study is starting years before a similar study for Naglazyme, which was done as a post-marketing commitment.  We will also conduct a study in non-ambulatory patients, which, along with the study in patients under five years of age, will encompass the spectrum of MPS IVA patients not included in the Phase 3 trial.  Enrollment in the Phase 3 pivotal study is on track for results in the second half of 2012, and its execution is BioMarin's highest product development priority."

The primary objective of the Phase 2, open-label, multinational clinical study is to evaluate the safety and tolerability of infusions of GALNS at a dose of 2.0 mg/kg/week over a 52-week period in ten to fifteen MPS IVA patients under five years of age.  The secondary objectives are to evaluate urinary keratan sulfate (KS) levels and growth velocity.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, amifampridine phosphate (3,4-diaminopyridine phosphate), which is currently in Phase III clinical development for the treatment of LEMS in the U.S., PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations related to the continued clinical development of its product candidate GALNS; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others:; results and timing of current and planned preclinical studies and clinical trials of GALNS; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning GALNS and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2010 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

 Contact:

 InvestorsMediaEugenia ShenBob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267 

 

 


'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
2. BioMarin to Host a Research and Development Day on December 8th
3. BioMarin Announces Third Quarter 2011 Financial Results
4. BioMarin to Present at the UBS Global Life Sciences Conference
5. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
6. BioMarin to Present at the Baird Health Care Conference
7. BioMarin to Present at the Wedbush Life Sciences Conference
8. BioMarin Announces Second Quarter 2011 Financial Results
9. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
10. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
11. BioMarin to Present at the William Blair Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017 Acute, Chronic and Prophylaxis GVHD ... a CAGR of 7% from 2016-2021 and CAGR of 3% from 2021-2027. ... 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn ... ... how you can exploit the future business opportunities emerging in this sector. ...
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an ... cycle portfolio and thought leadership at the 2017 ... a category leader award from KLAS. ... discussion focused on how market trends shape the ... particularly a sophisticated, comprehensive Patient Access solution. The ...
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 ... that positive Phase 1 clinical data for Nektar,s lead ... (RCC) were presented at ASCO GU 2017.  NKTR-214 is ... T cells and Natural Killer (NK) cell abundance directly ... on these immune cells.  The results were presented by ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... ... home healthcare, will join forces with Healthwise ® at HIMSS 2017 ... the industry leader in evidence-based health education, technology and services, will demonstrate a ...
(Date:2/18/2017)... , ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos ... , Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea ...
(Date:2/17/2017)... ... 2017 , ... Smiles by Seese is a comprehensive family dental practice ... leads the practice as a skilled and highly credentialed dentist who is qualified to ... patients of all ages with excellence in general, restorative, and cosmetic dentistry . ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... has been named a finalist in the 8th Annual DecisionHealth Platinum Awards in ... delivery system. Qualis Health’s work is recognized across multiple award categories, highlighting four ...
Breaking Medicine News(10 mins):